The impact of abiraterone and enzalutamide on hypokalemia incidence in patients with prostate cancer: a systematic review and meta-analysis. [PDF]
Lou Y, Fan D, Chen T, Xiong K.
europepmc +1 more source
Exploring Radiographic Progression-Free Survival in Diverse Subgroups of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Efficacy of Abiraterone and Enzalutamide. [PDF]
Özmen A, Tural D.
europepmc +1 more source
Abiraterone-Induced Hypokalemia and Hypophosphatemia: A Case Report. [PDF]
Safi A +10 more
europepmc +1 more source
Safety and Treatment Discontinuation of Novel Hormonal Therapies in Metastatic Hormone-Sensitive Prostate Cancer: An Exploratory Real-World Study. [PDF]
Millan-Ramos I +6 more
europepmc +1 more source
Empirical-Null Calibration Challenges Comparative CNS Safety Signals for Androgen-Receptor Pathway Inhibitors: A FAERS Re-Analysis. [PDF]
İnkaya A, Güngör HS.
europepmc +1 more source
Distinct Prognostic Roles of Grade Group and Intraductal Carcinoma of the Prostate in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. [PDF]
Ikeda J +10 more
europepmc +1 more source
Fulminant Hepatic Failure Following Initiation of Abiraterone in Metastatic Prostate Cancer: A Fatal Adverse Drug Reaction. [PDF]
Tilma E, Mark EB, Drewes AM.
europepmc +1 more source
Sequential Enzalutamide-Docetaxel Versus Abiraterone-Docetaxel Therapy in Castration-Resistant Prostate Cancer: A Subanalysis of the ENABLE Study. [PDF]
Kamiyama M +18 more
europepmc +1 more source
Editorial Comment on Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa. [PDF]
Arai S.
europepmc +1 more source

